UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.816

Sortiert nach

080 The proteome of hand eczema assessed by tape stripping

Journal of investigative dermatology, 2022-12, Vol.142 (12), p.S194-S194

2022

Link zum Volltext

Verfügbarkeit prüfen

The 1.4-A crystal structure of the S. pombe Pop2p deadenylase subunit unveils the configuration of an active enzyme

Nucleic acids research, 2007-05, Vol.35 (9), p.3153

2007

Link zum Volltext

Verfügbarkeit prüfen

10-year prevalence of contact allergy in the general population in Denmark estimated through the CE-DUR method

Contact dermatitis, 2007-10, Vol.57 (4), p.265-272

2007

Link zum Volltext

Verfügbarkeit prüfen

1582. Is Antibiotic Prophylaxis Needed for All Acute Variceal Bleeds in Decompensated Cirrhosis? A Retrospective Pilot Study

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S494-S495

2018

Link zum Volltext

Verfügbarkeit prüfen

168 EVALUATION OF THE FUNCTIONAL CCL2 PROMOTER POLYMORPHISM −2518A> G AS RISK FACTOR FOR SPONTANEOUS BACTERIAL PERITONITIS AND DEATH IN DECOMPENSATED LIVER CIRRHOSIS

Journal of hepatology, 2010, Vol.52, p.S73-S73

2010

Link zum Volltext

Verfügbarkeit prüfen

18856 The association between atopic dermatitis and hypertension: A systematic review and meta-analysis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB108-AB108

2020

Link zum Volltext

Verfügbarkeit prüfen

220 Predictors and cost of hospitalization for atopic dermatitis in US adults and children

Journal of investigative dermatology, 2017-05, Vol.137 (5), p.S37-S37

2017

Link zum Volltext

Verfügbarkeit prüfen

250 Direct healthcare cost of atopic dermatitis in the Swedish population

Journal of investigative dermatology, 2021-05, Vol.141 (5), p.S45

2021

Link zum Volltext

Verfügbarkeit prüfen

25442 Relationship between topical corticosteroid utilization and atopic dermatitis severity and burden: A population-based cross-sectional study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB58-AB58

2021

Link zum Volltext

Verfügbarkeit prüfen

25532 Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB7-AB7

2021

Link zum Volltext

Verfügbarkeit prüfen

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB96-AB96

2021

Link zum Volltext

Verfügbarkeit prüfen

27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB133-AB133

2021

Link zum Volltext

Verfügbarkeit prüfen

27489 Depth of response to abrocitinib in adults with moderate-to-severe atopic dermatitis (AD): Pooled analysis of monotherapy studies

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB148-AB148

2021

Link zum Volltext

Verfügbarkeit prüfen

27533 Comparative efficacy and safety of systemic therapies used in adult and adolescent moderate-to-severe atopic dermatitis (AD): A systematic literature review (SLR) and network meta-analysis (NMA)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB34-AB34

2021

Link zum Volltext

Verfügbarkeit prüfen

27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB155-AB155

2021

Link zum Volltext

Verfügbarkeit prüfen

28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB171-AB171

2021

Link zum Volltext

Verfügbarkeit prüfen

314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

32496 Efficacy and safety of abrocitinib according to geographies

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB161-AB161

2022

Link zum Volltext

Verfügbarkeit prüfen

33233 Long-term efficacy (to 68 weeks) of baricitinib in adult patients with moderate to severe atopic dermatitis (AD) who were treatment responders or partial responders and originally included in the combination topical corticosteroids study BREEZE-AD7

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB77-AB77

2022

Link zum Volltext

Verfügbarkeit prüfen

34297 Dupilumab provides long-term improvement in sleep loss in children, adolescents, and adults with atopic dermatitis

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB45-AB45

2022

Link zum Volltext

Verfügbarkeit prüfen

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB180-AB180

2022

Link zum Volltext

Verfügbarkeit prüfen

34599 Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB134-AB134

2022

Link zum Volltext

Verfügbarkeit prüfen

350 Examining the relationships among abrocitinib treatment, itch, skin pain and work and activity impairments in patients with atopic dermatitis: a mediation modelling analysis

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

351 Examining the relationships among abrocitinib treatment, itch, skin pain and dermatology-specific quality of life in patients with atopic dermatitis: a mediation modelling analysis

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.816

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.514)
Mit Volltextzugriff
(1.603)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.077)
Life Sciences & Biomedicine
(949)
Humans
(663)
Dermatology
(540)
Female
(347)
Male
(329)
Adult
(290)
Allergy
(238)
Middle Aged
(229)
Biological And Medical Sciences
(216)
Medical Sciences
(183)
Atopic Dermatitis
(165)
Dermatitis
(164)
Aged
(160)
Adolescent
(126)
Animals
(126)
Dermatitis, Allergic Contact - Etiology
(123)
Young Adult
(119)
Risk Factors
(100)
Allergic Diseases
(98)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(21)

Menü

Weitere Dienste

Einstellungen

080 The proteome of hand eczema assessed by tape stripping

The 1.4-A crystal structure of the S. pombe Pop2p deadenylase subunit unveils the configuration of an active enzyme

10-year prevalence of contact allergy in the general population in Denmark estimated through the CE-DUR method

1582. Is Antibiotic Prophylaxis Needed for All Acute Variceal Bleeds in Decompensated Cirrhosis? A Retrospective Pilot Study

168 EVALUATION OF THE FUNCTIONAL CCL2 PROMOTER POLYMORPHISM −2518A> G AS RISK FACTOR FOR SPONTANEOUS BACTERIAL PERITONITIS AND DEATH IN DECOMPENSATED LIVER CIRRHOSIS

18856 The association between atopic dermatitis and hypertension: A systematic review and meta-analysis

220 Predictors and cost of hospitalization for atopic dermatitis in US adults and children

250 Direct healthcare cost of atopic dermatitis in the Swedish population

25442 Relationship between topical corticosteroid utilization and atopic dermatitis severity and burden: A population-based cross-sectional study

25532 Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE

27489 Depth of response to abrocitinib in adults with moderate-to-severe atopic dermatitis (AD): Pooled analysis of monotherapy studies

27533 Comparative efficacy and safety of systemic therapies used in adult and adolescent moderate-to-severe atopic dermatitis (AD): A systematic literature review (SLR) and network meta-analysis (NMA)

27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE

28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

314 Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis

322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

32496 Efficacy and safety of abrocitinib according to geographies

33233 Long-term efficacy (to 68 weeks) of baricitinib in adult patients with moderate to severe atopic dermatitis (AD) who were treatment responders or partial responders and originally included in the combination topical corticosteroids study BREEZE-AD7

34297 Dupilumab provides long-term improvement in sleep loss in children, adolescents, and adults with atopic dermatitis

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

34599 Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results

350 Examining the relationships among abrocitinib treatment, itch, skin pain and work and activity impairments in patients with atopic dermatitis: a mediation modelling analysis

351 Examining the relationships among abrocitinib treatment, itch, skin pain and dermatology-specific quality of life in patients with atopic dermatitis: a mediation modelling analysis

Suchergebnisse filtern